| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Experimental Medicine and Pathology, University of Rome "La Sapienza," Rome, Italy;
Department of Medical Biochemistry, Göteborg University, Gothenburg, Sweden;
Institute of Biotechnology, Forschungszentrum Jülich, Jülich, Germany;
School of Dentistry, University of Copenhagen, Copenhagen, Denmark;¶
Cancer Research U.K., Breast Cancer Biology Group, Guy’s Hospital, London, United Kingdom; and||
NEUROMED, Istituto Neurologico Mediterraneo, Pozzilli, Italy
Tumors exploit several strategies to evade immune recognition, including the production of a large number of immunosuppressive factors, which leads to reduced numbers and impaired functions of dendritic cells (DCs) in the vicinity of tumors. We have investigated whether a mucin released by tumor cells could be involved in causing these immunomodulating effects on DCs. We used a recombinant purified form of the MUC1 glycoprotein, an epithelial associated mucin that is overexpressed, aberrantly glycosylated, and shed during cancer transformation. The O-glycosylation profile of the recombinant MUC1 glycoprotein (ST-MUC1) resembled that expressed by epithelial tumors in vivo, consisting of large numbers of sialylated core 1 (sialyl-T, ST) oligosaccharides. When cultured in the presence of ST-MUC1, human monocyte-derived DCs displayed a modified phenotype with decreased expression of costimulatory molecules (CD86, CD40), Ag-presenting molecules (DR and CD1d), and differentiation markers (CD83). In contrast, markers associated with an immature phenotype, CD1a and CD206 (mannose receptor), were increased. This effect was already evident at day 4 of DC culture and was dose dependent. The modified phenotype of DCs corresponded to an altered balance in IL-12/IL-10 cytokine production, with DC expressing an IL-10highIL-12low phenotype after exposure to ST-MUC1. These DCs were defective in their ability to induce immune responses in both allogeneic and autologous settings, as detected in proliferation and ELISPOT assays. The altered DC differentiation and Ag presentation function induced by the soluble sialylated tumor-associated mucin may represent a mechanism by which epithelial tumors can escape immunosurveillance.
This article has been cited by other articles:
|
|
 |
|
  D. Ilkovitch and D. M. Lopez Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec Blood, May 7, 2009; 113(19): 4729 - 4739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-M. Kuang, Q. Zhao, J. Xu, J.-P. Yun, C. Wu, and L. Zheng Tumor-Educated Tolerogenic Dendritic Cells Induce CD3{epsilon} Down-Regulation and Apoptosis of T Cells through Oxygen-Dependent Pathways J. Immunol., September 1, 2008; 181(5): 3089 - 3098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Tinder, D. B. Subramani, G. D. Basu, J. M. Bradley, J. Schettini, A. Million, T. Skaar, and P. Mukherjee MUC1 Enhances Tumor Progression and Contributes Toward Immunosuppression in a Mouse Model of Spontaneous Pancreatic Adenocarcinoma J. Immunol., September 1, 2008; 181(5): 3116 - 3125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ilkovitch, M. E. Handel-Fernandez, L. M. Herbert, and D. M. Lopez Antitumor Effects of Mucin 1/sec Involves the Modulation of Urokinase-Type Plasminogen Activator and Signal Transducer and Activator of Transcription 1 Expression in Tumor Cells Cancer Res., April 1, 2008; 68(7): 2427 - 2435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Napoletano, A. Rughetti, M. P. Agervig Tarp, J. Coleman, E. P. Bennett, G. Picco, P. Sale, K. Denda-Nagai, T. Irimura, U. Mandel, et al. Tumor-Associated Tn-MUC1 Glycoform Is Internalized through the Macrophage Galactose-Type C-Type Lectin and Delivered to the HLA Class I and II Compartments in Dendritic Cells Cancer Res., September 1, 2007; 67(17): 8358 - 8367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Tarp, A. L. Sorensen, U. Mandel, H. Paulsen, J. Burchell, J. Taylor-Papadimitriou, and H. Clausen Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat Glycobiology, February 1, 2007; 17(2): 197 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Mansour, E. Latz, and S. M. Levitz Cryptococcus neoformans Glycoantigens Are Captured by Multiple Lectin Receptors and Presented by Dendritic Cells. J. Immunol., March 1, 2006; 176(5): 3053 - 3061. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
